Skip to main content
SpringerLink
Log in

Role of Prostaglandin Synthesis and Cyclooxygenase-2 in Prostate Cancer and Metastasis

  • Chapter
Metastasis of Prostate Cancer

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 10))

Abstract

Metabolites of arachidonic acid, inclusive of prostatglandins (PGs), have been implicated in cancer for a number of years. In this overview, the evidence of the role of PGs and their interaction with endogenous hormones and exogenous (environmental) influences, predominately dietary factors, in the development and metastasis of prostate cancer, the mechanisms of action and approaches toward facilitating the design of effective strategies for the prevention and intervention of prostate cancer are considered. Included herein and apart from their traditionally thought of metabolic effects, PGs have been shown to function as biological response modifiers as evidenced from their effects on proliferation, apoptosis and immune responses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jaffe BM. Prostaglandins and cancer: An update. Prostaglandins 1974, 6:453–61.

    PubMed  CAS  Google Scholar 

  2. Karmali RA. Prostaglandins and cancer. Review. Prostaglandins 1980, 5:11–28.

    CAS  Google Scholar 

  3. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992, 52:5575–89.

    PubMed  CAS  Google Scholar 

  4. Levy. GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, colon cancer. FASEB J 1997, 11:234–47.

    PubMed  CAS  Google Scholar 

  5. Marnett LJ. Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyradicals as positive intermediates. Environ Health Perspect 1990, 88:5–12.

    PubMed  CAS  Google Scholar 

  6. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998, 48:6–29.

    PubMed  CAS  Google Scholar 

  7. Anonymous. Prostate cancer in the UK. J R Soc Health 1997, 117:156.

    Google Scholar 

  8. Xie WL, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: A target for non-steroidal anti-inflammatory drugs. Drug Dev Res 1992, 25:245–65.

    Google Scholar 

  9. Simmons D, Xie W, Chipman JG, Evett GE. Multiple cyclooxygenases: Cloning of a mitogen-inducible form, In: Prostaglandin, Leukotreines, Lipoxins and Paf . Bailey JM, ed., New York: Plenum Press, 1991:67–78.

    Google Scholar 

  10. O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxy-genase-2 in human tissue. FEBS Lett 1993, 330:156–60.

    PubMed  CAS  Google Scholar 

  11. Smith CJ, Morrow JD, Roberts LJ, Marnett LJ. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1). Biochem Biophys Res Commun 1993, 192:787–93.

    PubMed  CAS  Google Scholar 

  12. Samet JM, Fasano MB, Fonteh AN, Chilton FH. Selective induction of prostaglandin G/H synthase I by stem cell factor and dexamethasone in mast cells. J Biol Chem 1995, 270:8044–9.

    PubMed  CAS  Google Scholar 

  13. Murakami M, Matsumoto R, Urade Y, Austen KF, Arm JP. C-kit ligand mediates increased expression of cytosolic phospholipase A2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D2 synthase and increased ige-dependent prostaglandin D2 generation in immature mouse mast cells. J Biol Chem 1995, 270:3239–46.

    PubMed  CAS  Google Scholar 

  14. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988, 85:1412–6.

    PubMed  CAS  Google Scholar 

  15. Merlie JP, Fagan D, Mudd J, Needleman P. Isolation and characterization of the complementary DNA for sheep seminal vesicle prostaglandin endoperoxide synthase (cyclooxygenase). J Biol Chem 1988, 283:3550–5.

    Google Scholar 

  16. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald CA. Human platelet/ erythroleukemia cell prostaglandin G/H synthase: CDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991, 5:2304–12.

    PubMed  CAS  Google Scholar 

  17. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992, 89:7384–8.

    PubMed  CAS  Google Scholar 

  18. Jouzeau J-Y, Terlain B, Abid A, Nédélec E, Netter P. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997, 53:563–82.

    PubMed  CAS  Google Scholar 

  19. O’Banion MK, Winn VD, Young DA. CDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992, 89:4888–92.

    PubMed  CAS  Google Scholar 

  20. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS 10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992, 267:4338–4.

    PubMed  CAS  Google Scholar 

  21. DuBois RN, Awad J, Morrow J, 2nd, Roberts U, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994, 93:493–8.

    PubMed  CAS  Google Scholar 

  22. Smith WL, Meade EA, DeWitt DL. Interactions of PGH synthase isoenzymes 1 and 2 with NSAIDs. Ann NY Acad Sci 1994, 744:50–7.

    PubMed  CAS  Google Scholar 

  23. Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-src -inducible gene. Proc Natl Acad Sci USA 1989, 86:1178–82.

    PubMed  CAS  Google Scholar 

  24. Maier JA, Hla T, Maciag T. Cyclooxygenase is an immediate-early gene induced by interleukin-l in human endothelial cells. J Biol Chem 1990, 265:10805–8.

    PubMed  CAS  Google Scholar 

  25. Ryseck RP, Raynoschek C, Macdonald-Bravo H, Dorfman K, Mattei MG, Bravo R. Identification of an immediate early gene, pghs-B, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ 1992, 3:443–50.

    PubMed  CAS  Google Scholar 

  26. Needleman P, Isakson PC. Selective inhibition of cyclooxygenase 2. Sci Med 1998:26–35.

    Google Scholar 

  27. Wong E, Bayly C, Waterman HL, Riendeau D, Mancini JA. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double HIS513>arg and ILE523>val mutation. J Biol Chem 1997, 272:9280–6.

    PubMed  CAS  Google Scholar 

  28. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995, 15:179–84.

    PubMed  CAS  Google Scholar 

  29. Murakami M, Matsumoto R, Austen KF, Arm JP. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 1994, 269:22269–75.

    PubMed  CAS  Google Scholar 

  30. Morita I, Schindler M, Regier MK, Otto JC, Hon T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995, 270:10902–8.

    PubMed  CAS  Google Scholar 

  31. DeWitt D, Smith WL. Yes, but do they still get headaches. Cell 1995, 83:345–8.

    PubMed  CAS  Google Scholar 

  32. Eling TE, Curtis JF. Xenobiotic metabolism by prostaglandin H synthase. Pharmacol Ther 1992, 53:261–73.

    PubMed  CAS  Google Scholar 

  33. Badawi AF, Abadi AA, Habib SL, Mohammed MA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 expression in human urinary bladder cancer. Cancer Invest 2002, 20:651–656.

    PubMed  CAS  Google Scholar 

  34. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993, 268:6610–4.

    PubMed  CAS  Google Scholar 

  35. Kulmacz RJ, Lands WEM. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985, 260:12572–8.

    PubMed  CAS  Google Scholar 

  36. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994, 90:11693–7.

    Google Scholar 

  37. Rome LH, Lands WEM. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975, 72:4863–5.

    PubMed  CAS  Google Scholar 

  38. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995, 44:1–10.

    PubMed  CAS  Google Scholar 

  39. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG et al . Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994, 91:3228–32.

    PubMed  CAS  Google Scholar 

  40. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otoma S. NS-392, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro . Prostaglandins 1994, 47:55–9.

    PubMed  CAS  Google Scholar 

  41. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D et al . Mechanisms of selective inhibition of the inducible form of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994, 94:11202–6.

    Google Scholar 

  42. McKanna JA, Zhang MZ, Wang JL, Cheng H, Harris RC. Constitutive expression of cyclooxygenase-2 in rat vas deferens . Am J Physiol 1998, 275:R227–33.

    PubMed  CAS  Google Scholar 

  43. Lyson K. Indomethacin suppression of the estradiol-induced proliferative response of the seminal vesicals. Exp Clin Endocrinol 1984, 84:223–7.

    Article  PubMed  CAS  Google Scholar 

  44. Lyson K, Pawlikowski M. Suppression of proliferative response of the seminal vesicles to testosterone by inhibitors of prostaglandin synthesis. Testosterone, indomethacin, and proliferation in seminal vesicles. J Androl 1983, 4:167–70.

    PubMed  CAS  Google Scholar 

  45. Tjandrawinata RR, Hughes-Fulford M. Up-regulation of cyclooxygenase-2 by products-prostaglandin E2. Adv Exp Med Biol 1997, 407:163–70.

    PubMed  CAS  Google Scholar 

  46. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostate carcinoma cells. Br J Cancer 1997, 75:1111–8.

    PubMed  CAS  Google Scholar 

  47. Faas FH, Dang AQ, Pollard M, Hong XM, Fan K, Luckert PH, Schutz M. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol 1996, 156:243–8.

    PubMed  CAS  Google Scholar 

  48. Karmali RA. Eicosanoids in neoplasia. Prev Med 1987, 16:493–502.

    PubMed  CAS  Google Scholar 

  49. Ablin RJ, Shaw MW. Prostaglandin modulation of prostate tumor growth and metastases. Anticancer Res 1986, 6:327–8.

    PubMed  CAS  Google Scholar 

  50. Khan O, Hensby CN, Williams G. Prostacyclin in prostatic cancer: A better marker than bone scan or serum acid phosphatase. Br J Urol 1982, 54:26–31.

    Article  PubMed  CAS  Google Scholar 

  51. Dunzendorfer U, Zahradnik HP, Grster K. 13, 14-Dihydro-15-keto-prostaglandin F 2α in patients with urogenital tumors. Urol Int 1980, 35:171–5.

    Article  PubMed  CAS  Google Scholar 

  52. Rubenstein M, Shaw MW, McKiel CF, Ray, PS, Guinan. PD. Immunoregulatory markers in rats carrying dunning R3327 H G, or MAT-LYLU prostatic adenocarcinoma variants. Cancer Res 1987, 47:178–82.

    PubMed  CAS  Google Scholar 

  53. Shaw MW, Ablin RJ, Ray P, Rubenstein M, Guinan PD, McKiel CF Immunology of the Dunning R-. 3327 Rat prostate adenocarcinoma sublines: Plasma and tumor effusion prostaglandins. Am J Reprod Immunol Microbiol 1985, 8:77–9.

    PubMed  CAS  Google Scholar 

  54. Smith BI, Wills MR, Savory J. Prostaglandins and cancer. Ann Clin Lab Sci 1983, 13:359–65.

    PubMed  CAS  Google Scholar 

  55. Ablin RJ. Prostaglandins affect the tumor immune response in prostatic carcinoma. J Urol 1982, 127:997–8.

    PubMed  CAS  Google Scholar 

  56. Rose DP, Connolly JM. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991, 18:243–54.

    PubMed  CAS  Google Scholar 

  57. Drago JR, AI-Mondhiry HA. The effect of prostaglandin modulators on prostate tumor growth and metastasis. Anticancer Res 1984, 4:391–4.

    PubMed  CAS  Google Scholar 

  58. Tsujii M, DuBois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493–501.

    PubMed  CAS  Google Scholar 

  59. Subbaramaiah K, Telang N, Ramonetti JT, Araki R, DeVito B, Weksler BB, Dannenberg AJ. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996, 56:4424–9.

    PubMed  CAS  Google Scholar 

  60. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl -2 expression in LNCaP cells. Cancer Res 1998, 58:4245–9.

    PubMed  CAS  Google Scholar 

  61. Swan DK, Ford B. Chemoprevention of cancer: Review of literature. Oncol Nutr Forum 1997, 24:719–27.

    CAS  Google Scholar 

  62. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998, 77:511–5.

    PubMed  CAS  Google Scholar 

  63. Bucher C, Jordan P, Nickeleit V, Torhorst J, Mihatsch MJ. Relative risk of malignant tumors in analgesic abusers: Effect of intake of aspirin. Clin Nephrol 1999, 51:67–72.

    PubMed  CAS  Google Scholar 

  64. Magoha GA. Ten years experience with chronic prostatitis in africans. East Afr Med J 1996, 73:176–8.

    PubMed  CAS  Google Scholar 

  65. Bosland MC. Hormonal factors in carcinogenesis of the prostate and testis in human and in animal models. Prog Clin Biol Res 1996, 394:309–52.

    PubMed  CAS  Google Scholar 

  66. Armstrong B. Endocrine factors in human carcinogenesis. IARC Sci Publ 1982, 39:193–221.

    PubMed  Google Scholar 

  67. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982, 42:3232–9.

    PubMed  CAS  Google Scholar 

  68. Rioja LA, Sanz J. Carcinomas of the prostate: General concepts. Semin Oncol 1991, 18:2–8.

    PubMed  CAS  Google Scholar 

  69. Badawi AF, El-Sohemy A. Non-steroidal anti-inflammatory drugs in chemoprevention of breast and prostate cancer. Med Hypoth 2001, 57:167–8.

    CAS  Google Scholar 

  70. Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipids 1992, 27:798–803.

    PubMed  CAS  Google Scholar 

  71. Pienta KJ, Esper PS. Is dietary fat a risk factor for prostate cancer. J Natl Cancer Inst 1993, 85:1538–40.

    PubMed  CAS  Google Scholar 

  72. Badawi AF, Archer MC. Effect of hormonal status on the expression of the cyclooxygenase 1 and 2 genes and prostaglandin synthesis in rat mammary gland. Prostaglandins Other Lipid Mediat 1998, 56:167–81.

    PubMed  CAS  Google Scholar 

  73. Badawi AF, El-Sohemy A, Stephen LL, Archer MC. Modulation of the expression of cyclooxygenase 1 and 2 genes in the mammary gland: Role of dietary fat and hormonal status. Adv Exp Med Biol 1999, 469:119–24.

    PubMed  CAS  Google Scholar 

  74. Archer MC, el-Sohemy A, Stephen LL, Badawi AF. Molecular studies on the role of dietary fat and cholesterol in breast cancer induction. Adv Exp Med Biol 1997, 422:39–46.

    PubMed  CAS  Google Scholar 

  75. Badawi AF, El-Sohemy A, Stephen LL, Ghoshal AK, Archer MC. Effects of dietary n-3 and n-6 polyunsaturated fatty acids on the expression of cyclooxygenase-1 and -2 and P21RAS in rat mammary glands. Carcinogenesis 1998, 19:905–10.

    PubMed  CAS  Google Scholar 

  76. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995, 23:43–62.

    PubMed  CAS  Google Scholar 

  77. Castagnetta LA, Carruba G. Human prostate cancer: A direct role for estrogens. Ciba Found Symp 1995, 191:269–89.

    PubMed  CAS  Google Scholar 

  78. Signorello LB, Tzonou A, Mantzoros CS, Lipworth L, Lagiou P, Hsieh C et al . Serum steroids in relation to prostate cancer risk in case-control study (greece). Cancer Causes Control 1997, 8:632–6.

    PubMed  CAS  Google Scholar 

  79. Montie JE. A glimpse at the future of some endocrine aspects of prostate cancer. Prostate Suppl 1996, 6:57–61.

    PubMed  CAS  Google Scholar 

  80. Dearnaley DP. Cancer of the prostate. Br Med J 1994, 308:780–4.

    CAS  Google Scholar 

  81. Srinivasan G, Campbell E, Bashirelahi N. Androgen, estrogen, and progesterone receptors in normal and aging prostates. Microsc Res Techn 1995, 30:293–304.

    CAS  Google Scholar 

  82. Klein LA, Stoff JS, Ellis J. Acute effects of testosterone on serum PG levels in male dogs. Prostaglandins 1982, 24:467–73.

    PubMed  CAS  Google Scholar 

  83. Gupta C. The role of prostaglandins in masculine differentiation: Modulation of prostaglandin levels in the differentiating genital tract of the fetal mouse. Endocrinology 1989, 124:129–33.

    PubMed  CAS  Google Scholar 

  84. Rui II, Gordeladze JO, Gutvik KM, Purvis K. Prolactin desensitizes the prostaglandin el-dependent adenylyl cyclase in the rat prostate gland. Mol Cell Endocrinol 1984, 38:53–60.

    PubMed  CAS  Google Scholar 

  85. Takai K. Promotional effects of high fat diet on chemical carcinogenesis of the prostate. Japan J Urol 1991, 82:871–0.

    CAS  Google Scholar 

  86. Bosland MC, Oakley-Girvan I, Whittemore AS. Dietary fat, calories, and prostate cancer risk. J Natl Cancer Inst 1999, 91:489–91.

    PubMed  CAS  Google Scholar 

  87. Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994, 57:176–80.

    PubMed  CAS  Google Scholar 

  88. Kuller LH. Dietary fat and chronic diseases: Epidemiologic overview. J Am Diet Assoc 1997, 97:9–15.

    Google Scholar 

  89. Fischer S, von Schacky C, Schweer H. Prostaglandins E3 and F 3α are excreted in human urine after ingestion of n-3 polyunsaturated fatty acids. Biochem Biophys Acta 1988, 963:501–8.

    PubMed  CAS  Google Scholar 

  90. Nolan RD, Danilowicz RM, Eling TE. Role of arachidonic acid metabolism in the mitogenic response of balb/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 1988, 33:650–6.

    PubMed  CAS  Google Scholar 

  91. Hakeda Y, Harada S, Matsumoto T, Tezuka K, Higashino K, Kodama H et al . Prostaglandin F 2α stimulates proliferation of clonal osteoplastic MC3T3-E1 cells by up-regulation of insulin-like growth factor 1 receptors. J Biol Chem 1991, 266:21044–50.

    PubMed  CAS  Google Scholar 

  92. Pentland AP, Needleman P. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis. J Clin Invest 1986, 77:246–51.

    PubMed  CAS  Google Scholar 

  93. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L et al . Effects of non-steroidal anti-inflammatory drugs on proliferation and induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996, 52:237–45.

    PubMed  CAS  Google Scholar 

  94. Fürstenberger G, Marks F. Indomethacin inhibition of cell proliferation induced by the phorbol ester TPA is reversed by prostaglandin E2 in mouse epidermis in vivo. Biochem Biophys Res Commun 1987, 84:1103–8.

    Google Scholar 

  95. Fürstenberger WC, Marks F. Prostaglandins, epidermal hyperplasia and skin tumor promotion. Arachidonic Acid Metabolism and Tumor Promotion 1985, 49–72.

    Google Scholar 

  96. Verma AK, Ashendel CL, Boutwell RK. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1980, 40:708–15.

    Google Scholar 

  97. Fürstenberger G, Gross M, Marks F. Involvement of prostaglandins in the process of skin tumor promotion. In: Ecosanoids and Cancer. Thaler-Dao H, Crastes de Paulet A, Paoletti R, eds, New York: Raven Press, 1984:91–100.

    Google Scholar 

  98. Lupulescu A. Cytologic and metabolic effects of prostaglandins on rat skin. J Invest Dermatol 1977, 68:138–45.

    PubMed  CAS  Google Scholar 

  99. Craven PA, Saito R, DeRubertis FR. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 1983, 72:1365–75.

    PubMed  CAS  Google Scholar 

  100. Kawamura T, Akira T, Watanaba M, Kagitani Y. Prostaglandin E1 prevents apoptotic cell death in superficial dorsal horn of rat spinal cord. Neuropharmacology 1997, 36:1023–30.

    PubMed  CAS  Google Scholar 

  101. Kawamura T, Horie S, Maruyama T, Akira T, Imagawa T, Nakamura N. Prostaglandin E1 transported into cells blocks the apoptotic signals induced by nerve growth factor deprivation. J Neurochem 1999, 72:1907–4.

    PubMed  CAS  Google Scholar 

  102. Ottonello L, Gonella R, Dapino P, Sacchetti C, Dallegri F. Prostaglandin E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: Role of intracellular cyclic AMP levels. Exp Hematol 1998, 26:895–902.

    PubMed  CAS  Google Scholar 

  103. Kroll B, Kunz S, Tu N, Schwarz LR. Inhibition of transforming growth factor-β1 and UV light-induced apoptosis by prostanoids in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol 1998, 152:240–50.

    PubMed  CAS  Google Scholar 

  104. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58:362–6.

    PubMed  CAS  Google Scholar 

  105. Hixson L, Alberts D, Krutzsch M, Einspahr J, Brendel K, Gross PH et al. Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells. Cancer Epidemiol Biomarker Prev 1994, 3:433–8.

    CAS  Google Scholar 

  106. Lu S, Xie W, Reed T, Bradshaw WS, Simmons DL. Nonsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995, 92:7961–5.

    PubMed  CAS  Google Scholar 

  107. Elder DJE, Hague A, Hicks DJ, Paraskeva C. Different growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro -transformed adenoma relative to adenoma cell lines. Cancer Res 1996, 56:2273–6.

    PubMed  CAS  Google Scholar 

  108. Abramson SB, Weissmann G. The mechanisms of action of antiinflammatory drugs. Arthritis Rheum 1989, 32:1–9.

    PubMed  CAS  Google Scholar 

  109. Duggan DE, Hooke HF, Riskley AE, Shen TY, van Arman CG. Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 1977, 201:8–13.

    PubMed  CAS  Google Scholar 

  110. Shiff SJ, Qiao L, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits cell proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995, 96:491–503.

    PubMed  CAS  Google Scholar 

  111. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997, 57:2909–15.

    PubMed  CAS  Google Scholar 

  112. Piazza GA, Kulchak-Rahm AL, Krutzsch M, Sperl G, Shipp-Puranka N, Gross PH et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995, 55:3110–6.

    PubMed  CAS  Google Scholar 

  113. Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995, 87:1259–60.

    PubMed  CAS  Google Scholar 

  114. Battu S, Rigaud M, Beneytout JL. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29CL.19a. Anticancer Res 1998, 18:3579–83.

    PubMed  CAS  Google Scholar 

  115. Plescia O, Racis S. Prostaglandins as physiological immunoregulators. Prog Allergy 1988, 44:153–71.

    PubMed  CAS  Google Scholar 

  116. Goodwin JS, Bankhurst AD, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin; existence of a prostaglandin-producing suppressor cell. J Exp Med 1977, 146:1719–34.

    PubMed  CAS  Google Scholar 

  117. Baich CM, Doghert PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer cancer patients. Surgery 1984, 95:71–7.

    Google Scholar 

  118. Brunda MJ, Heberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980, 124:2682–7.

    PubMed  CAS  Google Scholar 

  119. Goodwin JS. Immunological effects of nonsteroidal anti-inflammatory drugs. Am J Med 1984, 77:7–15.

    PubMed  CAS  Google Scholar 

  120. Cantrow WD, Cheuing HT, Sundharadas G. Effects of prostaglandins on the spreading, adhesion and migration of mouse peritoneal macrophages. Prostaglandins 1978, 63:39–46.

    Google Scholar 

  121. Bockman RS. PGE inhibition of T-lymphocyte colony formation. J Clin Invest 1972, 64:812–21.

    Article  Google Scholar 

  122. Strausser HR, Humes JL. Prostaglandin synthesis inhibition: Effect on bone changes and sarcoma tumor induction in BALB/c mice. Int J Cancer 1975, 15:724–30.

    PubMed  CAS  Google Scholar 

  123. Lynch NR, Salomon JC. Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 1979, 62:117–21.

    PubMed  CAS  Google Scholar 

  124. Young MR, Duffie GP, Lozano Y, Young ME, Wright MA. Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic lewis lung carcinoma variants. Cancer Res 1990, 50:2973–8.

    PubMed  CAS  Google Scholar 

  125. Yamazaki H, Shimada T. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalyzed by human cytochrome P450 enzymes. Xenobiotica 1999, 29:231–41.

    PubMed  CAS  Google Scholar 

  126. Schwartz Z, Sylvia VL, Curry D, Luna MH, Dean DD, Boyan BD. Arachidonic acid directly mediates the rapid effects of 24,25-dihydroxyvitamin D3 via protein kinase C and indirectly through prostaglandin production in resting zone chondrocytes. Endocrinol 1999, 140:2991–3002.

    CAS  Google Scholar 

  127. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF. Prostaglandin H synthase and xenobiotic oxidation. Ann Rev Pharmacol Toxicol 1990, 30:1–45.

    CAS  Google Scholar 

  128. Smith BJ, Curtis JF, Eling TE. Bioactivation of xenobiotics by prostaglandin H synthetase. Chem Biol Interact 1991, 79:245–64.

    PubMed  CAS  Google Scholar 

  129. Murasaki G, Zenser TV, Davia BB, Cohen SM. Inhibition by aspirin of N-[4-(5-nitro-2-furyl-2-thiazoyl]formamide-induced bladder carcinogenesis. Carcinogenesis 1984, 5:53–5.

    PubMed  CAS  Google Scholar 

  130. Wild, D, Degan GH. Prostaglandin H synthetase-dependent mutagenic activity of heterocyclic aromatic amines of the IQ type. Carcinogenesis 1987, 8:541–5.

    PubMed  CAS  Google Scholar 

  131. Bosland MC. Animal models for the study of prostate carcinogenesis. J Cell Biochem 1992, 16H:89–98.

    CAS  Google Scholar 

  132. Thomson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC et al. Transgenic models for the study of prostate cancer. Cancer 1993, 71:1165–71.

    Google Scholar 

  133. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406–9.

    PubMed  CAS  Google Scholar 

  134. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995, 83:473–82.

    PubMed  CAS  Google Scholar 

  135. Waymouth C, Coman DR, Ward-Baily PF. Spontaneous tumors of the prostate gland in inbred strains of mice. J Natl Cancer Inst 1983, 70:199–20.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Population Science, Fox Chase Cancer Center, PA, Philadelphia, USA

    Alaa F. Badawi

Authors
  1. Alaa F. Badawi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Arizona College of Medicine, and the Arizona Cancer Center, Tucson, AZ, U.S.A

    Richard J. Ablin

  2. University of Cardiff, U.K

    Malcolm D. Mason

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Badawi, A.F. (2008). Role of Prostaglandin Synthesis and Cyclooxygenase-2 in Prostate Cancer and Metastasis. In: Ablin, R.J., Mason, M.D. (eds) Metastasis of Prostate Cancer. Cancer Metastasis – Biology and Treatment, vol 10. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-5847-9_5

Download citation

Publish with us

Policies and ethics

Search

Navigation